berk-n-acetylcysteinenac-2022.pdf (1.44 MB)View fileThis item contains files with download restrictions
Next page
Previous page
1/1
Switch ViewSwitch between different file views
Thumbnail viewList viewFile view
2 filesFullscreen
N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial
posted on 2022-07-13, 00:00authored byJ Sarris, G Byrne, D Castle, C Bousman, G Oliver, L Cribb, S Blair-West, V Brakoulias, D Camfield, C Ee, S Chamoli, M Boschen, Olivia DeanOlivia Dean, N Dowling, R Menon, J Murphy, N J Metri, T P Nguyen, A Wong, R Jordan, D Karamacoska, S L Rossell, Michael BerkMichael Berk, C H Ng
N-acetyl cysteine (NAC) augmentation in the treatment of obsessive-compulsive disorder: A phase III, 20-week, double-blind, randomized, placebo-controlled trial
History
Journal
Progress in Neuro-Psychopharmacology and Biological Psychiatry